pembrolizumab,enfortumab vedotin
astellas,seagen,merck
['pembro', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ev-103']
pros from ev-103 cohort k: 1l ev+pembro or ev in cis-inelig la/muc: ev+p: sustained pain, insomnia, constipation (24 wks). transient diarrhea at 3 wk ev+p: 45% mod-severe pain at t0--&gt;clinically sig worst/avg pain, pain interference similar in ev arm
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology